Drug Combination Details
| General Information of the Combination (ID: C89846) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Temozolomide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | GIC-1 | Glioblastoma multiforme | Homo sapiens | |||
| Experimental
Result(s) |
TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling. | |||||
